All Posts: clinical trials
-
Could a Georgetown Lab Finding Lead to New Treatment in Pancreatic Cancer?
For the first time, new research by Georgetown scientists shows potential to make immunotherapy effective in pancreatic cancer by combining it with a drug that makes cancer cells more responsive to immunotherapy. The research is now in a phase 2 clinical trial being tested in human patients.
Category: Lombardi Stories
-
Understanding Immunotherapy Resistance Leads to New Therapeutic Strategies — and Hope
Samir Khleif, MD, an immunologist and professor of oncology at Georgetown Lombardi, is working to understand why some cancers become resistant to immunotherapy, and how that resistance can be overcome.
Category: Lombardi Stories
-
The Winn Awards is looking for the next cohort of Cancer Development Award scholars
Applications accepted through May 13 through the Robert A. Winn Diversity in Clinical Trials Award Program (Winn Awards), which seeks to increase diversity in clinical trials and transform the clinical research landscape.
Category: DEI Funding Opportunities
-
Biology Behind New Drug Used to Treat Triple-Negative Breast Cancer Uncovered
How TTP488 (azeliragon), an experimental drug, impairs aggressive, triple-negative breast cancer from metastasizing has been uncovered at the cellular level, according to researchers at Georgetown University’s Lombardi Comprehensive Cancer Center.
Category: News Release
-
New Study Finds Personalized mRNA Vaccine Given with Immunotherapy Reduces Recurrence in High-Risk Melanoma Patients
A new study conducted by an international team of researchers, including clinical investigators at Georgetown University’s Lombardi Comprehensive Cancer Center, demonstrates that a personalized cancer mRNA vaccine combined with immunotherapy reduces recurrence and improves survival for people with advanced melanoma.
Category: Lombardi Stories
-
Ruesch Symposium Participants Encourage Patients to Consider Clinical Trials
(December 2, 2022) — After being diagnosed with pancreatic cancer in April 2021, Jan Baird-Adams, a librarian from Maryland, had lots of questions for her oncologist, Marcus Noel, MD, associate professor of oncology and director of the Clinical Research Management Office at Georgetown Lombardi Comprehensive Cancer Center. “Dr. Noel and his staff were incredibly kind […]
Category: Lombardi Stories
-
The Society for Immunotherapy of Cancer (SITC) Publishes a Checklist to Maximize the Benefit to Patients for Clinical Trials in Immuno-oncology
MILWAUKEE (October 6, 2022)— No uniform method has been established to predict the probability of success for individual clinical trials. To help identify clinical trials with a high likelihood of offering benefit to patients, the Society for Immunotherapy of Cancer (SITC) brought together a team of experts in immuno-oncology to create a conceptual framework for […]
Category: News Release
-
Advanced Melanoma Survival Improves Significantly When Immunotherapy is Given Before Targeted Therapy
The findings, coupled with results from another recent clinical trial, mark significant advances in the treatment of melanoma. WASHINGTON (September 27, 2022) — A clinical trial led by clinicians at Georgetown Lombardi Comprehensive Cancer Center showed a remarkable 20 percent advantage in the two-year overall survival rate for people with advanced melanoma who first received […]
Category: News Release
-
Trial Stopped Early: Giving Immunotherapy Before Targeted Rx Improves Survival in Advanced Melanoma
WASHINGTON (November 15, 2021) — More people with advanced melanoma survive for two years or more when they receive a combination of two immunotherapy drugs given before a combination of two targeted therapies, if needed, compared to people who start treatment with targeted therapies. The finding comes from a clinical trial that was stopped early […]
Category: News Release
-
Clinical Trial Result Leads to New Treatment Option for Hard-to-Treat Breast Cancer
(June 4, 2021) — A clinical trial exploring a new treatment for breast cancer found that women with a hard-to-treat form of the disease lived longer without the disease coming back following treatment. The trial was conducted at sites around the world, including Georgetown Lombardi Comprehensive Cancer Center. “This finding represents a significant step forward […]
Category: Lombardi Stories